BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, June 20, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2018

View Archived Issues

Fixing nuclear transport helps cells cope with premature, normal aging

Read More

Combinations offer new antibiotic possibilities

Read More

Researchers find novel mutation in CLCC1 gene tied to retinitis pigmentosa

Read More

New rat model of diabetic cardiopathy described

Read More

Aeromics initiates phase I study of AER-271 in healthy volunteers

Read More

APC11 has prognostic significance in colorectal cancer

Read More

Renal anemia treatment: new oral HIF prolyl hydroxylase inhibitor promotes EPO production in rodents

Read More

New abzymes presented for diagnosing multiple sclerosis

Read More

Initiation of phase II clinical trial of BPN-14770 in fragile X syndrome

Read More

miRagen launches phase II study of MRG-201

Read More

Positive phase I results announced for Vivus' VI-0106

Read More

New NFE2L2 activators identified at GlaxoSmithKline

Read More

Aurigene Discovery Technologies patents BRD4 inhibitors

Read More

Janssen Pharmaceutica discovers new menin/MLL interaction inhibitors

Read More

Dihydroceramide desaturase inhibitors presented by Centaurus Therapeutics

Read More

Hitgen describes Rho-associated protein kinase inhibitors

Read More

Vidac begins phase IIb trial of VCA-1102 in actinic keratosis

Read More

Kamada receives scientific advice from EMA for phase III trial of inhaled AAT

Read More

First patient enrolled in phase II study of subcutaneous MABp1 in hidradenitis suppurativa

Read More

SRI and Ionis enter research agreement to explore combination of technologies

Read More

European Commission grants marketing approval to Verkazia for severe vernal keratoconjunctivitis

Read More

Scynexis releases phase IIb study data for SCY-078 in vulvovaginal candidiasis

Read More

Arbutus offers update on pipeline progress

Read More

PPCS gene mutations linked to dilated cardiomyopathy

Read More

Zynerba starts pivotal study of ZYN-002 gel in fragile X syndrome

Read More

[177Lu]EB-PSMA-617 shows promising safety and efficacy in patients with mCRPC

Read More

[11C]LSN-3172176 brain PET tracer shows potential for quantification of M1 receptor in humans

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing